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Impaired endothelial function has been shown to limit exercise in coronary artery disease (CAD) patients and has been implicated
in myocardial ischemia. However, the association of endothelial function and ischemia on peak exercise oxygen consumption
(VO2) has not been previously reported. A total of 116 CAD patients underwent standard exercise stress testing, during which
VO2 was measured. On a separate day, endothelial-dependent and -independent function were assessed by ultrasound using flow-
mediated arterial vasodilation (FMD) and sublingual glyceryl trinitrate administration (GTNMD) of the brachial artery. Patients
with exercise-induced myocardial ischemia had lower FMD than nonischemic patients (3.64± 0.57 versus 4.98± 0.36, P = .050),
but there was no diﬀerence in GTNMD (14.11± 0.99 versus 15.47± 0.63, P = .249). Analyses revealed that both FMD (P = .006)
and GTNMD (P = .019) were related to peak VO2. However, neither the presence of ischemia (P = .860) nor the interaction
of ischemia with FMD (P = .382) and GTNMD (P = .151) was related to peak VO2. These data suggest that poor endothelial
function, potentially via impaired NO production and smooth muscle dysfunction, may be an important determinant of exercise
capacity in patients with CAD, independent of myocardial ischemia.
1. Introduction
Under normal physiological conditions, exercise-induced
increases in myocardial oxygen demand are met by coronary
vasodilation and increased oxygen delivery, thus preventing
ischemia or perfusion defects [1]. Vasodilation during exer-
cise is, in part, contingent upon the vascular endothelium
[2, 3] and endothelial dysfunction may limit skeletal muscle
oxygen delivery and exercise capacity. For example, impaired
endothelial function has been associated with poorer exercise
treadmill time in CAD patients [4] and in postcardiac trans-
plant patients [5].
Endothelial dysfunction is widely implicated in car-
diovascular disease and its complications [6]. Compared
to matched controls, patients with coronary artery disease
(CAD) have a greater degree of endothelial dysfunction
[7, 8]. In addition, patients with exercise-inducedmyocardial
ischemia have impaired endothelial function compared to
nonischemic patients [4]. It is possible that endothelial dys-
function may result in failure of arterial vasodilation during
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exercise [9], thus compromising oxygen supply and precipi-
tating ischemia in a CAD population [10].
The primary aim of the current study was to assess
impact of exercise-induced myocardial ischemia on the
relationship between endothelial function, as measured by
flow mediated dilatation in the brachial artery (FMD) and
peak oxygen consumption (VO2) during symptom limited
exercise testing in stable CAD patients. It was hypothesized
that endothelial function would be positively correlated to
VO2, that patients who experienced ischemia during exercise
would have greater degrees of endothelial dysfunction,
and that there would be a significant interaction between
ischemia and endothelial function in the prediction of VO2,
such that the relationship between endothelial function and
VO2 would be strongest in patients without ischemia.
2. Materials and Methods
2.1. Participants. Patients were participants in a randomized
controlled trial, the results of which have been previously
reported [11–13]. Patients were included in the current
secondary analyses if they had complete endothelial function
and exercise testing data at baseline. As such, of the 145
patients recruited, a total of 116 patients were used in the
current analyses. Patients not included in the analyses did not
diﬀer from those included on age, sex, medication status, or
medical comorbidities. All patients that were recruited had
documented coronary artery disease with prior evidence of
inducible exercise ischemia. Patients were excluded from the
study if they had baseline blood pressure >200/120mmHg,
LVEF <30%, history of MI, CABG, or PCI in the last 3
months, or had severe electrophysiological disorders. The
study was approved by the Institutional Review Boards of
both Duke University Medical Center and the Durham Vet-
erans Aﬀairs Medical Center. Signed informed consent was
obtained from all patients prior to their participation. None
of the authors have any conflict of interests or competing
interests with the content of the paper.
2.2. Measurement of Endothelial Function. Participants were
removed from all antianginal medications at least 48 hrs
prior to testing, with the exception of 23 patients who
remained on medications (21 beta-blockers, 9 long-acting
nitrates, and 7 calcium channel blockers) due to adverse car-
diac profiles. To control for this potential confounder, being
on or oﬀ medications during the endothelial function test
was included in the analyses as a covariate. During the
morning following at least an 8 hour fast, endothelial func-
tion was assessed in participants using flow-mediated arterial
vasodilation (for further details see [14]). The technique,
which conforms to published guidelines [15], involves the
digital capture and storage of high-resolution end-diastolic
(ECG R-wave synchronized) longitudinal B-mode images of
the brachial artery. Images were obtained at rest, during reac-
tive hyperemia induced by 5 minutes of forearm ischemia,
and following sublingual glyceryl trinitrate administra-
tion (GTNMD) using an ultrasound imaging system with
a 7–11MHz linear-array transducer and an Aspen acquisi-
tion system (Acuson, Mountain View, California).
2.3. Graded Exercise Test. On a separate visit and after
resumption of all antianginal medications (for which 16
participants were not taking antianginal medications), par-
ticipants performed a maximal graded exercise test on a
motor-driven treadmill (Quinton, model Q5000) using the
Duke-Wake Forrest protocol [16]. The electrocardiogram
was continuously monitored at rest, during exercise, and
throughout recovery with a 12-lead trace being printed at 1-
minute intervals. Blood pressure was measured at rest and
during each workload with an automated BPmonitor (Accu-
tracker model 4240; Suntech). Oxygen consumption (VO2)
was measured during exercise by respiratory gas exchange
analysis with a calibrated metabolic cart (Sensormedics,
model 2900; Yorba Linda, CA), using a breath-by-breath
technique. VO2 data were averaged over 20 second intervals,
and peak VO2 was taken as the highest 20 second average
during the last three minutes of the test. Every minute during
exercise patients were asked to rate chest pain (1–10 scale)
and perceived exertion (Borg 6–20 scale), by pointing to
hand held charts. Ischemia was determined by a senior car-
diologist and was defined as ST depression >1.0mm for at
least 3 beats. All electrocardiogram readings were made by
an experienced senior cardiologist.
2.4. Data Analysis. Student t-tests, χ2 analyses, and general
linear models (used when covariates were required) were
used to assess diﬀerences in demographic and exercise vari-
ables between patients who had exercise-inducible ischemia
and those who did not exhibit ischemia during the exer-
cise test. Current hypertensive status was defined by use
of antihypertensive medication. All significantly diﬀerent
demographic and exercise variables were used as covariates in
the multivariate analyses. As BMI was significantly diﬀerent
between the groups and was entered into the main models,
absolute peak VO2 (L/min) and not peak VO2 relative to
body weight (mL/kg/min) were used for statistical purposes.
This was done to prevent body weight being adjusted for
twice. Conventional general linear models were used to test
the relationships between endothelial function, exercise per-
formance, and ischemia. In total four models were estimated:
model 1 tested the independent eﬀects of FMD and ischemia
on peak VO2 during the exercise test; model 2 tested the
joint eﬀect of FMD and ischemia on peak VO2; model 3
tested the independent eﬀects of GTNMD and ischemia on
peak VO2 during the exercise test; model 4 tested the joint
eﬀect of GTNMD and ischemia on peak VO2. All models
used brachial artery vessel size, age, medication status during
the FMD test, and BMI as covariates. All statistical analyses
were performed using SAS (version 8.2, Cary, NC), with
significance set at P < .05.
3. Results and Discussion
3.1. Clinical Characteristics. The clinical characteristics of
the 34 patients who exhibited exercise inducible ischemia
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Table 1: Clinical and demographic variables for those patients with and without exercise-induced ischemia.
M (SD) Ischemic Nonischemic χ2/t/F P
n 34 82
Age (years) 66 (11) 61 (10) 2.26 .026
BMI (kg·m−2) 27.9 (4.1) 30.6 (5.3) 2.68 .009
% Women (n) 35 (12) 27 (21) 1.11 .293
% On meds during FMD (n) 12 (4) 23 (19) 1.97 .161
% Hypertensive (n) 41 (14) 60 (49) 3.34 .068
% Dyslipidemic (n) 89 (73) 32 (94) 0.73 .394
% Diabetic (n) 19 (23) 5 (15) 1.05 .306
% Current smoker (n) 12 (15) 3 (9) 0.72 .396
FMD (%)∗ 3.64 (0.57) 4.98 (0.36) 3.92 .050
GTNMD (%)∗ 14.11 (0.99) 15.47 (0.63) 1.34 .249
∗Corrected M (SE), adjusting for vessel size.
BMI: body mass index, ETT: exercise tolerance test, FMD: flow-mediated dilatation, GTNMD: GTN-mediated dilatation.
and the 84 patients who were not ischemic are summarized
in Table 1. The ischemic group was significantly older and
had a significantly lower BMI compared to the nonischemic
group. There were no diﬀerences in any other characteristics,
including resting blood pressure and heart rate, as measured
in a seated position prior to the start of the stress test.
FMD, controlling for vessel size, was significantly lower in the
ischemic group, whereas there was no significant diﬀerence
in GTNMD between the groups. Table 2 shows that there
were no significant diﬀerences in exercise treadmill time,
chest pain, or level of perceived exertion between the two
groups.
3.2. Relationship between Endothelial Function, Ischemia, and
Peak VO2. The results of the sequence of general linear
models for peak VO2 are presented in Table 3, with the
parameter estimate b (analogous to unstandardized regres-
sion coeﬃcients) and P-values shown for each model. The
results for Models 1 and 2 revealed that of the covariates,
age and brachial artery vessel size were related to peak VO2
during exercise. From Model 1, we observed a main eﬀect
for FMD, but not ischemia, on peak VO2 levels, such that
lower levels of FMD were related to lower peak VO2 values.
Figure 1 shows the main eﬀect of FMD (split by quartiles) on
VO2. The FMD × ischemia interaction in Model 2 was not
significant, indicating that there was no evidence for a joint
eﬀect of these variables on peak VO2. A similar pattern of
results were seen in Models 3 and 4. Age, BMI, and brachial
artery vessel size were all related to peak VO2. Model 3
revealed a main eﬀect for GTNMD, and not ischemia,
on peak VO2, and a nonsignificant interaction between
GTNMD and ischemia in Model 4. These results found that
reductions in GTNMD were associated with reduced peak
VO2, and that there were no main or interaction eﬀects of
ischemia on peak VO2. Of note, these results did not sub-
stantially change when those patients who were taking medi-
cations during the FMD test were removed from the analyses.
3.3. Discussion. The current study found that both endo-




















Figure 1: The relationship between endothelial function (quartiles
of flow-mediated dilatation: FMD) and peak oxygen uptake (Peak
VO2), adjusting for vessel size, age, and body mass index.
associated with lower levels of peak VO2 in CAD patients
undergoing exercise treadmill testing. This relationship
remained significant after adjusting for age, BMI, and
brachial artery vessel size. However, neither the presence of
ischemia during the exercise test nor the interaction of
ischemia with FMD or GTNMD was related to peak VO2. As
such, the major new finding of this study is that endothelial-
dependent and -independent vasodilator function is related
to exercise capacity independently of whether a patient expe-
riences myocardial ischemia. In line with previous studies
[4, 10, 17], we did find that, as a group, ischemic patients
had lower FMD values than nonischemic patients.
Both exercise capacity and endothelial function have
been shown to predict clinical events in patients with CAD
[18, 19]. Additionally, both have been shown to improve with
exercise training [20–24]. Reviews of the previous research
in this area has shown that endothelial dysfunction seems
to limit exercise capacity and that this may be through
multiple mechanisms [2, 3, 25], including altered production
of NO [23], prostanoids [26], or endothelin [27]. However, it
should be noted that the vast majority of this work has come
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Table 2: Exercise variables for those patients with and without exercise-induced ischemia.
M (SD) Ischemic Non-ischemic χ2/t/F P
Total ETT time (s) 463 (142) 448 (172) 0.43 .666
Peak VO2 (mL·kg−1·min−1) 19.7 (5.0) 20.1 (6.2) 0.30 .765
Peak VO2 abs (L·min−1) 1.62 (0.56) 1.83 (0.64) 1.68 .095
Resting SBP (mmHg) 139.5 (18.7) 136.7 (19.4) −0.71 .478
Resting DBP (mmHg) 76.7 (8.7) 77.6 (8.4) 0.53 .596
Resting HR (bpm) 66.5 (10.8) 65.3 (10.3) −0.56 .575
Peak SBP (mmHg)∗ 190 (4) 180 (3) 3.53 .063
Peak DBP (mmHg)∗ 88 (2) 86 (1) 0.78 .380
Peak HR (mmHg)∗ 130 (4) 126 (2) 0.72 .399
Peak RPE 17.0 (2.1) 16.8 (1.9) 0.52 .606
Peak R 1.02 (0.08) 1.03 (0.12) 0.43 .670
% Had chest pain (n) 50 (17) 55 (45) 0.23 .632
Peak pain rating (Borg scale) 2.3 (2.7) 2.7 (2.8) 0.58 .560
% Max test (n: >85% predicted HR) 12 (4) 22 (18) 1.62 .203
∗Corrected M (SE), adjusting for resting levels.
ETT: exercise tolerance test, VO2: oxygen consumption, SBP: systolic blood pressure, DBP: diastolic blood pressure, HR: heart rate, RPE: Borg rating of
perceived exertion.
Table 3: Endothelial function variables and ischemia predicting peak oxygen consumption (VO2) during exercise testing, adjusting for vessel
size, medication status during the FMD test, age, and BMI.
Variable
Model 1 Model 2 Model 3 Model 4
b P b P b P b P
Ischemia −0.02 .860 −0.12 .433 −0.04 .970 −0.31 .189
FMD 0.04 .006 −0.01 .866 — — — —
FMD × ischemia — — 0.03 .382 — — — —
GTNMD — — — — 0.02 .019 −0.01 .546
GTNMD × ischemia — — — — — — 0.02 .151
FMD: flow-mediated dilatation, GTNMD: GTN-mediated dilatation
Note: value labeled b is the unstandardized regression coeﬃcient from mixed model. Ischemia was scored as ischemia = 1 and no-ischemia = 2. Dash indicates
that the variable was not included in the model. Model 1 refers to main eﬀect of FMD and ischemia on peak VO2, Model 2 refers to their interaction eﬀects
on peak VO2, Model 3 represents the main eﬀects of GTNMD and ischemia on peak VO2, and Model 4 represents their interaction eﬀects on peak VO2.
from healthy participants and animal studies. Our finding
that both FMD and GTNMD were related to VO2 is consis-
tent with the idea of a multimechanistic process. Previous
research has suggested that a significant response or rela-
tionship seen with both endothelial-dependent (FMD) and
-independent (GTNMD) stimuli, as in the current study, is
indicative of both impaired endothelial function and smooth
muscle dysregulation [28, 29], and thus, may contribute to
the relationship between vasoreactivity and exercise capacity.
It has been suggested that endothelial dysfunction can
lead to paradoxical coronary vasoconstriction during exer-
cise, thus helping to precipitate ischemia [30]. Endothelial
dysfunction is associated with reduced exercise treadmill
time in CAD patients [4] and in postcardiac transplant
patients [5]. Therefore, we had anticipated that the relation-
ship between endothelial function and VO2 would be weaker
or even nonexistent in those patients with ischemia. How-
ever, the lack of an interaction between FMD or GTNMD
and ischemia indicated that this was not true in the current
study.
One inherent limitation of cross-sectional research, as
in the current study, is that we are unable to infer direc-
tionality of the endothelial function-oxygen consumption
relationship. Previous research has suggested that endothelial
dysfunction precedes oxygen consumption limitation. For
example, an exercise intervention in heart failure patients
found that improvements in exercise capacity were propor-
tional to the beneficial changes seen in agonist-mediated
endothelial dilation [21]. However, more work is needed to
elucidate the true nature of the FMD-VO2 relationship. It is
possible that some underlying factor, which was not mea-
sured in the current study, directly influences both the endo-
thelium and oxygen requirements such that the relationship
seen is an artifact of the third variable. For example, elevated
C-reactive protein or homocysteinemia have both been
shown to influence vasoreactivity [31, 32] and neither were
assessed in the current population. Also, we were not able
to assess the potential eﬀect of shear rate as this data was
not recorded and this may account for some of the observed
relationship.
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Patients in the present study were withdrawn from their
anti-ischemic medications prior to and during the endothe-
lial function testing but remained on medications during
the exercise test. This is likely to account for the relatively low
incidence of exercise-induced ischemia seen during the exer-
cise test. It is impossible to truly estimate the residual eﬀects
of medications on the outcome measures. However, a pre-
vious study found that endothelial function was not altered
in patients when they took their normal regimen of cardiac
medications compared to when they were medication-free
[33]. This study suggests that medication utilization has
small eﬀects on endothelial function. Of course, it is also pos-
sible that the taking of medications during the exercise stress
test may have had a beneficial eﬀect on exercise performance
and myocardial perfusion, which may have influenced the
results. However, this does reflect what a patient would
normally experience during daily living.
Finally, given that men and women seem to have diﬀerent
CAD courses and patterns of CAD outcomes [34, 35] and
that endothelial function has been postulated as one reason
for such diﬀerences [36], it would have been interesting to
include further analyses which had a sex interaction or were
sex-specific. However, it should be noted that only around
30% of the sample were women, which did not provide
enough power for us to conduct such analyses. The need for
such future studies in this area is further strengthened by
the fact that when we included sex as an additional covariate
there was a reduction in the estimates for the eﬀects of FMD
(change from 0.04 to 0.02) and GTNMD (change from 0.02
to 0.01). Though it is possible that this reduction in eﬀect
seen when sex was added to the model could be a conse-
quence of over-fitting [37], there are other potential physio-
logical explanations, such as the fact that women are thought
to have greater microvascular dysfunction relative to men
[38, 39]. As the current study did not have the capacity to
disentangle such issues further work to assess the sex-specific
nature of this relationship should be conducted.
4. Conclusions
Endothelial-dependent and -independent vascular dysfunc-
tion were associated with reduced oxygen consumption in
CAD patients, and these relationships were independent
of myocardial ischemia. These data suggest that impaired
vascular reactivity via reduced NO production and smooth
muscle dysfunction may be an important determinant of
exercise capacity in patients with CAD. Further research is
needed to delineate the exact mechanisms of these relation-
ships.
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